Allarity Therapeutics, Inc.
NASDAQAllarity Therapeutics enters its Q1 2026 earnings call on May 22 having shed 13% over the past week, and the tension is straightforward: a clinical-stage biotech with no revenue, a binary pipeline, and a print arriving in days. The stock closed at $1.35 on Friday, down 11% in a single session. That reverses a solid one-month bounce of roughly 13%. Peers in the micro-cap biotech…
Snapshot as of 16 May 2026
Allarity Therapeutics enters its Q1 2026 earnings call on May 22 having shed 13% over the past week, and the tension is straightforward: a clinical-stage biotech with no revenue, a binary pipeline, and a print arriving…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALLR — free to start on ORTEX.
Sign up for free →Open ALLR on ORTEX